SAN DIEGO, March 13, 2022 (GLOBE NEWSWIRE) — Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of NRx Pharmaceuticals, Inc. NRXP NRXPW))) securities between June 1, 2021 and November 4, 2021, both dates inclusive (the “Class Period”) have until Monday, March 21, 2022 to seek appointment as lead plaintiff in Dal Bosco v. NRx Pharmaceuticals, Inc., No. 22-cv-00066 (D. Del.). Commenced in the District of Delaware on January 18, 2022 , the NRx Pharma class action lawsuit charges NRx as well as certain of its top executives with violations of the Securities Exchange Act of 1934.
If you suffered significant losses and wish to serve as lead plaintiff of the NRx Pharma class action lawsuit, please provide your information by clicking here. You can also contact attorney J.C. Sanchez of Robbins Geller by calling 800/449-4900 or via e-mail at [email protected]. Lead plaintiff motions for the NRx Pharma class action lawsuit must be filed with the court no later than Monday, March 21, 2022.
[WATCH NOW] Chris Capre, former hedge fund trader, teaches you how to trade options like a pro in even the most volatile markets. Click Here to Watch on YouTube!
CASE ALLEGATIONS: NRx is a clinical-stage small molecule pharmaceutical company that develops various therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. NRx’s products include, among others, ZYESAMI, an investigational pre-commercial drug for COVID-19 related respiratory failure. In June 2021, NRx announced that it filed an application with the U.S. Food and Drug Administration (“FDA”) requesting Emergency Use Authorization (“EUA”) for ZYESAMI (Aviptadil-acetate) to treat critically ill COVID-19 patients suffering with respiratory failure.
The NRx Pharma class action lawsuit alleges that, throughout the Class Period, defendants made false and misleading statements and failed to disclose that: (i) the ZYESAMI EUA application contained…